Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Nasopharyngeal Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Gemcitabine 23Specimen Handling 20130-nm albumin-bound paclitaxel 15Magnetic Resonance Spectroscopy 13Irinotecan 13Biopsy 12Fluorouracil 11Leucovorin 10Oxaliplatin 9pembrolizumab 7Cyclophosphamide 6Cisplatin 6Cetuximab 6Albumin-Bound Paclitaxel 6fludarabine 5Nivolumab 5durvalumab 4Taxes 4Radiosurgery 4Pemetrexed 4Capecitabine 4trastuzumab deruxtecan 3olaparib 3irinotecan sucrosofate 3dehydroftorafur 3aldesleukin 3Radiotherapy 3Immunoglobulin G 3Exercise 3Disulfides 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × camrelizumab × 30 days × Clear all
NCT06361888 2026-05-28

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Hutchmed

Phase 2/3 Recruiting
502 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡